Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- Pre Market Stock News Brief
Dec 01, 2008 10:05 AM
- FOOTNOTES: Recent Auditor Changes
Jun 19, 2006 05:15 PM
- FOOTNOTES: Recent Auditor Changes
Jun 16, 2006 05:15 PM
- FOOTNOTES: Recent Auditor Changes
Jun 15, 2006 05:15 PM
- FOOTNOTES: Recent Auditor Changes
Jun 14, 2006 05:15 PM
- FOOTNOTES: Recent Auditor Changes
Jun 13, 2006 05:15 PM
- FOOTNOTES: Recent Auditor Changes
Jun 12, 2006 05:15 PM
- FOOTNOTES: Recent Auditor Changes
Jun 09, 2006 05:15 PM
- FOOTNOTES: Recent Auditor Changes
Jun 08, 2006 05:15 PM
- 3RD UPDATE: Bird-flu Concerns Knock Airlines, Asian Currencies
May 24, 2006 07:51 PM
- Vical Announces Strategic Restructuring and Staff Reduction
Nov 21, 2008 06:30 AM
- Vical Executive Alain Rolland Named AAPS Fellow
Nov 17, 2008 06:30 AM
- Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
Nov 12, 2008 06:30 AM
- U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant
Nov 06, 2008 06:30 AM
- Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Programs
Nov 05, 2008 06:30 AM
- Vical to Present at Upcoming Investor Conferences
Nov 04, 2008 06:30 AM
- Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results
Oct 29, 2008 06:30 AM
- Vical to Present at Upcoming Investor Conferences
Oct 23, 2008 06:31 AM
- Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
Oct 08, 2008 06:30 AM
- Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
Oct 07, 2008 06:30 AM
Analyst Ratings
|
|
Share Performance
|
Period
|
VICL
|
Compare to S&P
|
| YTD |
-73.88 %
|
-57.21 %
|
| 4 Weeks |
-33.13 %
|
-27.72 %
|
| 12 Weeks |
-65.31 %
|
-51.92 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -14.29 %
|
|
EPS Growth in Last Year: 0.00 %
|
|
Sales Growth in Last Quarter: -72.08 %
|
|
Sales Growth in Last Quarter: 89.60 %
|
|
|
